Genus plc (OTCMKTS:GENSF) Sees Large Growth in Short Interest

Genus plc (OTCMKTS:GENSFGet Free Report) was the target of a large growth in short interest in January. As of January 30th, there was short interest totaling 37,249 shares, a growth of 633.5% from the January 15th total of 5,078 shares. Based on an average trading volume of 60 shares, the short-interest ratio is currently 620.8 days. Based on an average trading volume of 60 shares, the short-interest ratio is currently 620.8 days.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Genus in a research report on Thursday, November 20th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy”.

Get Our Latest Stock Report on Genus

Genus Price Performance

GENSF opened at $37.25 on Thursday. Genus has a 52 week low of $35.00 and a 52 week high of $37.25. The business’s 50 day moving average is $35.68 and its two-hundred day moving average is $35.02.

Genus Company Profile

(Get Free Report)

Genus plc, trading on the OTCMKTS under the symbol GENSF, is a global leader in innovative animal genetics and breeding solutions. The company operates through two primary business segments: ABS and PIC. ABS focuses on bovine genetics, offering dairy and beef cattle semen, advanced reproductive technologies and digital herd management tools. PIC specializes in porcine genetics, providing breeding stock, genetic evaluation services and production support aimed at optimizing growth performance, health and sustainability across the global swine industry.

With origins dating back to its establishment in 1933 as the British Dairy Cattle Breeders’ Society, Genus has expanded through strategic acquisitions and organic growth to build a leading position in animal biotechnology.

Featured Articles

Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.